America's Biotech
Acceleration Zone.
Curing what kills us, faster.
A privately initiated biomedical innovation district designed to compress therapy timelines from a decade to under two years. So that treatments for cancer, Alzheimer's, heart disease, and other chronic conditions reach patients while they can still benefit.
The constraint is not science.
It is structure.
We have therapies that can treat cancer, reverse neurodegeneration, and address the root causes of chronic disease. What we don't have is an environment built to get them to patients in time. Neovia is that environment.
Regulatory Bottleneck
Life-saving therapies are trapped in 10–15 year approval pipelines. AI has compressed discovery timelines by 10x, but the regulatory environment hasn't changed in decades. The gap between what science can do and what the system allows is widening.
Capital Inefficiency
When timelines are long and failure rates exceed 90%, capital sits on the sidelines. Compress the timeline and you fundamentally change the investment equation. Every dollar of R&D investment becomes 5 to 10 times more efficient.
Geopolitical Urgency
China, Singapore, and the UAE are building fast-track biotech environments. The U.S. risks losing its leadership position not because of inferior science, but because of a regulatory environment designed for a different era.
SEZ Precedent
Special economic zones have a proven track record of accelerating industries. Shenzhen. Dubai. Singapore. The model works. It has never been applied to U.S. biomedical innovation at this scale.
Four forces are converging
for the first time.
This is the first moment in history where infrastructure, policy, science, and capital can be realigned around speed.
AI Compressed Discovery
AI has reduced drug discovery timelines by 10x. The bottleneck is no longer the lab. It is the regulatory path between lab and patient.
U.S. Competitiveness at Risk
China, Singapore, and Saudi Arabia are building fast-track biotech environments with billions in sovereign capital. U.S. policy openness is increasing in response.
Legal Foothold Exists
Expanded Right to Try frameworks, validated surrogate endpoint pathways, and growing bipartisan support for regulatory modernization create a foothold for accelerated clinical deployment on U.S. soil.
Capital Awaiting Structure
Billions have flowed into biotech and therapeutic development. Institutional capital is waiting for an environment where compressed timelines and reduced regulatory risk fundamentally change the return profile.
These forces are converging now. The question is not whether a U.S. biotech acceleration zone will be built. It is who will build the first one.
A biomedical innovation district
built for speed.
Neovia combines three elements that have never been co-located in a single U.S. environment.
Regulatory Sandbox
Accelerated FDA pathways using validated surrogate endpoints, Expanded Right to Try frameworks, and provisional reimbursement models. Developed with constitutional attorneys and federal policy experts.
Purpose-Built Infrastructure
Wet labs, AI-driven discovery platforms, GMP manufacturing, and clinical trial facilities. Co-located in a single district designed for biomedical speed and scale.
World-Class Talent & Research
A single destination where leading scientists, biotech companies, and clinical teams work side by side to get treatments for cancer, neurodegeneration, and chronic disease to patients in 18 to 24 months.
Who is building Neovia.
Neovia's leadership combines decades of experience in governance, biotech strategy, and large-scale development.
Mark Hamilton
45+ years building alternative governance systems and parallel economic frameworks. Economist, investor, and author.
Wallace Hamilton
Entrepreneur and strategist leading ground-up execution across systems, alliances, infrastructure, and capital strategy.
José L. Cordeiro
MIT engineer, futurist. Founding faculty, Singularity University. Co-author of The Death of Death.
Taavi Kotka
Architect of Estonia's digital government. Creator of the world's first e-Residency program.
Advisory Board
Selective positions across biotech, AI drug discovery, regulatory strategy, and development.
Advisory participation is structured with defined scope across regulatory strategy, infrastructure development, and scientific oversight. Neovia operates within American legal and economic frameworks.
Research domains
and institutional relationships.
Neovia works with scientists at the frontier of chronic disease, cancer treatment, neurodegeneration, and regenerative medicine.
Our scientific network includes researchers affiliated with the LEV Foundation, Sierra Sciences, ARPA-H, 21st Century Medicine, Ora Biomedical, European Wellness Biomedical Group, and the Regenerative Medicine Foundation.
Full scientific advisory details available upon request.
People are dying from diseases
we have the science to treat.
Cancer. Alzheimer's. Heart disease. Diabetes. Parkinson's. The science to treat these conditions is advancing faster than at any point in human history. But a regulatory system that takes 10 to 15 years to move a treatment from discovery to patient means that progress is not reaching the people who need it. Meanwhile, other nations are building environments designed to move faster. The question is whether America will lead or follow.
For policymakers, scientists, and institutional partners who share this priority, we welcome the conversation.
Voices Of The Movement
Hear directly from the scientists, founders, investors, and pioneers leading the charge to cure disease, extend life, and transform the future of healthcare.
Mark Hamilton: The Missing Puzzle Piece to Curing Aging and Death
José Cordeiro: The Death of Death
Steve Horvath, PhD
Principal Investigator at Altos Labs | Creator of the Horvath Epigenetic Aging Clock
Michael Ringel, PhD
COO | Life Biosciences
Mehmood Khan, MD
CEO | Hevolution Foundation
Dr. Bill Andrews: Pioneer of Telomere Research & Anti-Aging Science
Dr. Greg Fahy: Turning Back Time Through Thymus Rejuvenation & Immune Renewal
Dr. Aubrey De Grey: Reaching Longevity Escape Velocity
Vijay Vaswani
CEO & Co-Founder | Omniscope
Dr. Jean Hebert: From Repairing Brain Damage to Tissue Replacement
Bill Faloon: Fighting Decline with Science, Supplements, and Contrarian Thinking
Bernard Siegel; From Courtroom to Congress—Accelerating Cures with Policy & People
Ivan Murgunov: Multidirectional Rejuvenation Could Add 20 Years to Life
Dr. Matt Kaeberlein: Science That Could Save Your Life (And Your Dog's)
Dr. David Wood: Outrun Aging Before It Takes More Lives
Neal VanDeRee
Melissa Peterson
Gennady Stolyarov II
Jim Marchant
Josephine Musco
Kai Micah
Sagar Chopra
Clinton Hughes
Dr Ines
Dr Peter Muran
Jason Steinbrunn
Get in touch.
Whether you are a researcher, policymaker, institutional partner, or investor, and you believe the U.S. should lead the next era of biomedical innovation, we would like to hear from you.
Committed Founding Partners
FOUNDER & CEO OF BIOVIVA SCIENCES
Liz Parrish
Liz Parrish is a respected voice in gene therapy and the founder of BioViva Sciences, a company dedicated to advancing regenerative medical technologies. Her focus is on accelerating scientific pathways that address age-related diseases through targeted cellular interventions.
As an early supporter of Neovia, her leadership reinforces the city’s commitment to practical, patient-centered innovation.
Key Highlights
Founder of one of the world’s most recognized gene therapy startups
Advocate for medical freedom and accelerated biotech access
Signed Neovia’s LOI to support deregulated therapeutic development
FOUNDER & CEO OF SIERRA SCIENCES
Dr. Bill Andrews
Dr. Andrews is a renowned molecular biologist with over three decades of experience in genetic research and therapeutic development.
He is the founder of Sierra Sciences, a biotech company at the forefront of exploring ways to address cellular aging mechanisms. With dozens of patents and a career rooted in scientific rigor, Dr. Andrews brings world-class credibility to Neovia’s biotech vision.
Key Highlights
Holds over 60 patents in molecular biology and telomere research
Former Director of Molecular Biology at Geron Corporation
Committed to advancing science outside of bureaucratic bottlenecks
+ Many More
Copyrights 2026 | Neovia | Terms & Conditions